Abstract
The cocrystallization of lamotrigine and valproic acid affords an ionic cocrystal with improved dissolution rate and mechanical properties. The multidrug crystal has a stoichiometry that is known to positively impact the pharmacokinetics of the parent compounds. As such, the new form is a suitable epileptic treatment. From a crystal engineering perspective, the structure is sustained by a complex multimolecular motif that includes each conformer in both the protonated and deprotonated state. Statistical and computational analysis reveals that the presence of ancillary H-bond donors in an R12(4)DD (or R22(8)DD) fashion is critical to the ionization state of the components.
| Original language | English |
|---|---|
| Pages (from-to) | 5308-5313 |
| Number of pages | 6 |
| Journal | Crystal Growth and Design |
| Volume | 19 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 4 Sep 2019 |